4
Changes in Ownership
Denali Therapeutics Inc. Filed Acc 0001209191-21-002342
President and CEO sold 88,334 shares at an average $74.96 ($6,621,782)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Watts Ryan J. President and CEO | 2021-01-04 | Sale | −1,300 | $65.21 | $84,768 | 2,410,012 | I: show line 1 in the form |
| Watts Ryan J. President and CEO | 2021-01-04 | Sale | −1,700 | $66.63 | $113,265 | 2,408,312 | I: show line 2 in the form |
| Watts Ryan J. President and CEO | 2021-01-04 | Sale | −1,224 | $68.26 | $83,552 | 2,407,088 | I: show line 3 in the form |
| Watts Ryan J. President and CEO | 2021-01-04 | Sale | −9,900 | $70.02 | $693,181 | 2,397,188 | I: show line 4 in the form |
| Watts Ryan J. President and CEO | 2021-01-04 | Sale | −11,896 | $70.82 | $842,479 | 2,385,292 | I: show line 5 in the form |
| Watts Ryan J. President and CEO | 2021-01-04 | Sale | −8,683 | $71.77 | $623,218 | 2,376,609 | I: show line 6 in the form |
| Watts Ryan J. President and CEO | 2021-01-04 | Sale | −9,443 | $72.63 | $685,852 | 2,367,166 | I: show line 7 in the form |
| Watts Ryan J. President and CEO | 2021-01-04 | Sale | −7,322 | $73.78 | $540,189 | 2,359,844 | I: show line 8 in the form |
| Open-market sales · 88,334 sh · avg $74.96 · $6,621,782 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Watts Ryan J. President and CEO | 2021-01-04 | Grant or award · Restricted Stock Units | +60,000 | 60,000 | D: show line 19 in the form | |||||
| Watts Ryan J. President and CEO | 2021-01-04 | Grant or award · Stock Option (right to buy) | +180,000 | 180,000 | D: show line 20 in the form |
Loading xslF345X03/doc4.xml…